Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blow to Ranbaxy Drug Research Plans (India)

This article was originally published in PharmAsia News

Executive Summary

Medicines for Malaria Venture (MMV), a World Health Organization agency, has announced that it is pulling out of its partnership with Ranbaxy Laboratories Ltd. to develop a anti-malarial drug. Since 2003, Ranbaxy, India's second-largest drug manufacturer, has been working with MMV to create a man-made version of Arterolane, a Chinese herbal remedy for malaria. Ranbaxy recently completed Phase II clinical trials on Arterolane. MMV had also performed several studies on the drug. MMV representatives say the decision to end their involvement in the project was the result of Arterolane's less-than-stellar performance in those trials. Despite the setback, Ranbaxy has said it will continue to develop the new drug and hope to have it ready to market by 2011. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel